ReviewFrontiers in microbiology2013
Current scenario of peptide-based drugs: the key roles of cationic antitumor and antiviral peptides.
Review in Frontiers in microbiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
92 citing papers in PubMed, 1 synthesis or guideline pooled it, 212 citations in OpenAlex.
- Animal venoms as a source of antiviral peptides active against arboviruses: a systematic review.Archives of virology · 2022Pooled it
- A hepcidin homolog fromVirulence · 2026Article
- PMAVP: A Mamba-Inspired Deep Learning Framework for Antiviral Peptide Identification and Functional Activity Prediction.International journal of molecular sciences · 2026Article
- Bacterial Acyl Carrier Proteins Are a Cytoplasmic Target for Different Cationic Antimicrobial and Antibiofilm Peptides.International journal of molecular sciences · 2026Article
- Next-generation antiviral peptides: AI-driven design, translational delivery platforms, and future therapeutic directions.Virus research · 2025Review
- Design, Synthesis, and Biological Evaluation of New Analogs of Aurein 1.2 Containing Non-Proteinogenic Amino Acids.Molecules (Basel, Switzerland) · 2025Article
- Exploring the Interaction of RBD with Human β Defensin Type 2 Point Mutants: Insights from Molecular Dynamics Simulations.The journal of physical chemistry. B · 2025Article
- NanoMarine therapeutics: a new wave in drug delivery from oceanic bioresources targeting colon cancer via miRNA modulation.Frontiers in genetics · 2025Review
- Antimicrobial Peptides: Mechanisms, Applications, and Therapeutic Potential.Infection and drug resistance · 2025Review
- Review
- Review
- Lung antimicrobial proteins and peptides: from host defense to therapeutic strategies.Physiological reviews · 2024Review
- Insights into therapeutic peptides in the cancer-immunity cycle: Update and challenges.Acta pharmaceutica Sinica. B · 2024Review
- Nanobody peptide conjugate: a novel CD163 based broad neutralizing strategy against porcine reproductive and respiratory syndrome virus.Journal of nanobiotechnology · 2024Article
- Lysozyme: A Natural Product with Multiple and Useful Antiviral Properties.Molecules (Basel, Switzerland) · 2024Review
- Application Value of Antimicrobial Peptides in Gastrointestinal Tumors.International journal of molecular sciences · 2023Review
- The Research Progress of Bioactive Peptides Derived from Traditional Natural Products in China.Molecules (Basel, Switzerland) · 2023Review
- Characterization of a novel peptide mined from the Red Sea brine pools and modified to enhance its anticancer activity.BMC cancer · 2023Article
- Antiviral polysaccharide and antiviral peptide delivering nanomaterials for prevention and treatment of SARS-CoV-2 caused COVID-19 and other viral diseases.Journal of controlled release : official journal of the Controlled Release Society · 2023Review
- Therapeutic Peptides for Treatment of Lung Diseases: Infection, Fibrosis, and Cancer.International journal of molecular sciences · 2023Review
32 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cationic antimicrobial peptides (AMPs) and host defense peptides (HDPs) show vast potential as peptide-based drugs. Great effort has been made in order to exploit their mechanisms of action, aiming to identify their targets as well as to enhance their activity and bioavailability. In this review, we will focus on both naturally occurring and designed antiviral and antitumor cationic peptides, including those here called promiscuous, in which multiple targets are associated with a single peptide structure. Emphasis will be given to their biochemical features, selectivity against extra targets, and molecular mechanisms. Peptides which possess antitumor activity against different cancer cell lines will be discussed, as well as peptides which inhibit virus replication, focusing on their applications for human health, animal health and agriculture, and their potential as new therapeutic drugs. Moreover, the current scenario for production and the use of nanotechnology as delivery tool for both classes of cationic peptides, as well as the perspectives on improving them is considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.